Pasireotide vs MK-677

Overview

Pasireotide and MK-677 represent opposite approaches to growth hormone (GH) modulation. Pasireotide (Signifor) is an FDA-approved somatostatin analog that suppresses GH secretion, used to treat conditions of GH excess like Cushing’s disease and acromegaly. MK-677 (ibutamoren) is a non-approved growth hormone secretagogue that stimulates GH release, researched for conditions of GH deficiency and aging. They are functional opposites.

Key Facts

Aspect	Pasireotide	MK-677
Brand Name	Signifor, Signifor LAR	Ibutamoren (research)
Type	Somatostatin analog	GH secretagogue
Effect on GH	Suppresses	Stimulates
FDA Status	Approved	Not approved
Mechanism	SSTR1,2,3,5 agonism	Ghrelin receptor agonism

Opposite Mechanisms

Factor	Pasireotide	MK-677
GH Direction	Decreases	Increases
Clinical Goal	Reduce excess GH	Increase deficient GH
IGF-1 Effect	Decreases	Increases
Target Population	GH excess diseases	GH deficiency/aging

Why Compare Opposites?

Understanding both ends of GH modulation helps clarify:

• GH physiology
• Different clinical needs
• Mechanism diversity
• Risk-benefit trade-offs

Mechanism Comparison

Aspect	Pasireotide	MK-677
Receptor Target	Somatostatin receptors	Ghrelin receptor (GHSR)
Receptor Subtypes	SSTR1, 2, 3, 5	GHSR1a
Pituitary Effect	Inhibits GH release	Stimulates GH release
Hypothalamic Effect	GHRH suppression	Mimics ghrelin

Pasireotide Mechanism

1. Somatostatin Receptor Agonism

   • High affinity for SSTR5
   • Also binds SSTR1, 2, 3
   • Broader receptor profile than octreotide
   • Inhibits hormone secretion

2. GH/IGF-1 Suppression

   • Reduces GH release from pituitary
   • Lowers circulating GH
   • Decreases IGF-1
   • Treats acromegaly

3. ACTH Suppression

   • Inhibits ACTH release
   • Treats Cushing’s disease
   • Via SSTR5 on corticotrophs

MK-677 Mechanism

1. Ghrelin Receptor Agonism

   • Mimics ghrelin at pituitary
   • Stimulates GH release
   • Does not affect cortisol
   • Oral bioavailability

2. GH/IGF-1 Increase

   • Increases GH pulses
   • Elevates IGF-1
   • Maintains GH pulsatility
   • Dose-dependent response

3. Metabolic Effects

   • Increases appetite (ghrelin effect)
   • May affect body composition
   • Improves nitrogen balance

Clinical Applications

Pasireotide Approved Uses

Indication	Formulation	Evidence
Cushing’s disease	Signifor (SC)	Phase 3 trials
Acromegaly	Signifor LAR (IM)	Phase 3 trials

MK-677 Research Applications

Area	Status	Evidence
GH deficiency	Researched	Moderate
Sarcopenia	Researched	Low-Moderate
Sleep quality	Observed	Low
Body composition	Researched	Low

Evidence Quality

Factor	Pasireotide	MK-677
FDA Approval	Yes	No
Phase 3 Trials	Completed	None for approved use
Safety Database	Established	Limited
Post-Marketing	Available	N/A
Overall Evidence	High	Low-Moderate

Pasireotide Trials

Trial	Indication	Outcome
Phase 3 Cushing’s	Cushing’s disease	Effective, approved
Phase 3 Acromegaly	Acromegaly	Effective, approved
PAOLA study	Acromegaly	Superior to octreotide

MK-677 Studies

Study Type	Finding	Quality
GH increase	Robust 2-3x increase	Moderate
Body composition	Mixed results	Low
Elderly studies	Some benefits	Low-Moderate
Long-term	Limited data	Low

Side Effect Profiles

Pasireotide

Effect	Frequency	Notes
Hyperglycemia	Very common (>50%)	Major concern
GI effects	Common	Diarrhea, nausea
Cholelithiasis	Common	Gallstones
QT prolongation	Possible	Monitor ECG
Injection site	Common	Local reactions

MK-677

Effect	Frequency	Notes
Increased appetite	Very common	Ghrelin effect
Water retention	Common	GH effect
Blood glucose increase	Common	GH effect
Numbness/tingling	Occasional	GH effect
Lethargy	Occasional	Initial

Glucose Effects Comparison

Factor	Pasireotide	MK-677
Glucose Impact	Significant increase	Modest increase
Mechanism	Decreases insulin secretion	GH antagonizes insulin
Severity	Major clinical concern	Monitoring recommended
Diabetes Risk	High	Moderate

Administration

Aspect	Pasireotide	MK-677
Route	SC or IM (LAR)	Oral
Convenience	Injection required	Oral (convenient)

Regulatory Status

Aspect	Pasireotide	MK-677
FDA	Approved (2012)	Not approved
EMA	Approved	Not approved
WADA	Permitted (medical)	Prohibited
Availability	Prescription	Research chemical

Cost Comparison

Factor	Pasireotide	MK-677
Cost	Very high (~$10,000+/month)	Low (~$50-100/month research)
Insurance	Usually covered for approved uses	Not covered
Quality	Pharmaceutical	Variable

Who Would Use Each

Pasireotide Candidates

Condition	Rationale
Cushing’s disease	Approved, ACTH suppression
Acromegaly	Approved, GH/IGF-1 suppression
Octreotide non-responders	Broader receptor profile

MK-677 Interest

Candidate	Rationale
GH deficiency research	Increases GH
Aging research	GH decline interest
Body composition	Research interest
Sleep quality	Anecdotal reports

Summary

Factor	Pasireotide	MK-677
GH Effect	Suppresses	Stimulates
FDA Status	Approved	Not approved
Indications	Cushing’s, acromegaly	Research only
Route	Injection	Oral
Cost	Very high	Low
Glucose Effects	Major concern	Moderate concern
Evidence Level	High	Moderate

Key Takeaways

1. Opposite mechanisms: Pasireotide suppresses GH; MK-677 increases GH
2. Different uses: Pasireotide for GH excess; MK-677 research for GH deficiency
3. Pasireotide is FDA-approved: For Cushing’s disease and acromegaly
4. MK-677 is not approved: Research chemical only
5. Both affect glucose: Pasireotide more severely
6. MK-677 is oral: Convenience advantage over injections
7. Cost difference huge: Pharmaceutical vs research chemical pricing
8. WADA status differs: MK-677 prohibited; pasireotide permitted (medical)

---

This comparison is for educational purposes only. Pasireotide is FDA-approved and requires prescription for approved indications. MK-677 is not approved and is prohibited by WADA.